Extending immunosuppressive drug coverage for the lifetime of kidney patients, instead of only covering dialysis, would be a cost-effective way for the federal government to reduce the costs of posttransplant care while improving clinical outcomes for patients.
An adolescent patient with poor social support who has already lost one transplanted kidney due to complications of nonadherence may not automatically be inappropriate to list for a second transplant if he can prove his ability to adhere to the demands of a dialysis regimen.
The guidelines for patients’ eligibility for bariatric surgery have not changed since 1991, although recent data suggest there may be indications for broadening application of the surgery.
A discussion of the ethical issues raised by a patient’s request for off-label, prophylactic bariatric surgery to prevent diabetes mellitus type 2 (DM type 2).